AI in clinical trials is often promised as a fix for slow recruitment, and a new agreement between AstraZeneca and Oracle puts that claim to a practical test. On 20 October 2026 the companies announced a non-binding collaboration to use AI and deidentified real-world data to help find eligible patients for trials earlier and to support safety monitoring, starting with a hypertension programme in Abu Dhabi with the healthcare company M42. This explainer describes how such systems generally work, what the companies have and have not said, and what evidence would show whether the approach helps. It is not medical advice.
AI in clinical trials: key takeaways
- The AstraZeneca and Oracle agreement is non-binding and discloses no financial terms, timeline or technology names.
- The stated aims are earlier identification of eligible patients, wider trial access and stronger safety monitoring.
- AstraZeneca says it will not receive patient-identifiable information, and each project is reviewed separately.
- General explanations below are labelled and are not details of the companies’ systems.
- No results exist yet, so the effect on recruitment speed is unknown.
Why recruitment is slow: the case for AI in clinical trials
General background: trials set strict eligibility rules, such as a diagnosis, a test result or a treatment history, and the patients who meet them are scattered across many clinics and health systems. Finding them often depends on a doctor remembering a study exists, or on staff reading records by hand. When too few patients enrol, a trial can take longer or fail to finish. The companies’ releases describe recruitment as one of the starting points, and the Oracle’s release says the aim is to connect more patients to trials.
How AI in clinical trials could help find patients
In general terms, a system can search deidentified health records for the criteria a trial requires and flag likely matches to care teams, who then decide whether to approach a patient. AI tools can help with parts of that task, such as reading free-text clinical notes. This description is ours and reflects common approaches, not a specification of the Oracle or AstraZeneca system, which the releases do not describe. The releases stress that clinicians would identify patients, and that the work operates under the governance of the health systems delivering care.
The Abu Dhabi hypertension programme
According to AstraZeneca’s version of the announcement, the first programme in Abu Dhabi with M42 aims to help clinical teams identify patients with uncontrolled hypertension, put guideline-directed care in place and improve trial recruitment. Hypertension is a common risk factor for heart disease and stroke, as the WHO fact sheet on hypertension explains. Oracle’s version does not mention the project. No patient numbers, trial design or start date have been published.
Safety monitoring: what AI in clinical trials could add
The companies say they believe the collaboration can strengthen safety monitoring. In general, routine-care data can reveal side effects that trials are too small or too short to detect, and AI can help scan large volumes of records for patterns. The releases give no detail about what signals would be tracked, how often or by whom. We therefore treat this as an aim and note that safety conclusions from observational data need careful review.
AI in clinical trials: the continuous learning model
Both releases describe a continuous learning model, in which what is learned from research and routine care feeds back into how studies are designed and how patients are treated. The companies say they plan shared governance, reusable technical components and agreed outcome measures, and that they will later assess extending the work across disease areas and geographies. Initial areas that could be covered include oncology, cardiovascular, renal and metabolic conditions, respiratory and immunology, and rare disease. These are possibilities named in the announcement and not commitments, and the agreement does not state which will be pursued first.
Questions clinicians and patients may ask
This section is our general framing and not a company statement. A clinician might ask how a patient was flagged, what data were used and whether the flag could be wrong. A patient might ask who decided to contact them, whether their records were seen in identifiable form, and whether joining a study is optional. The releases say the data are deidentified and that clinicians stay in charge of care, which suggests such questions should have clear answers, but the companies have not published the procedures that would let outsiders check.
Limits and risks of AI in clinical trials
- Records can be incomplete or inconsistent, which can lead to missed or wrongly flagged patients.
- If the data come mostly from certain hospitals or groups, recruitment may not reflect the wider population.
- Flagging a patient is not consent; a clinician must still approach the patient and the patient must agree.
- AI tools need validation, and releases rarely describe error rates.
These are general risks for tools of this kind, and we have no evidence that they apply in this programme. They explain why the companies’ emphasis on governance and review matters.
What evidence would show AI in clinical trials works
This section is our suggestion and not a company plan. Useful measures would include the time from study start to enrolment target, the share of flagged patients who turn out to be eligible, the proportion who agree to take part, and whether enrolled patients are representative. The releases refer to agreed outcome measures but do not list them. Until results are published, claims that AI speeds up trials remain expectations.
What is not known
- Which technology and models will be used.
- How many hospitals, clinicians and patients are involved.
- When the Abu Dhabi programme starts and how long it runs.
- Whether any AstraZeneca trial is linked to the programme.
Risks and caveats on AI in clinical trials claims
- The agreement is non-binding and may change.
- Benefits described are aims and not results.
- General explanations here describe typical approaches, not this system.
- This is news reporting, not medical advice.
In our assessment, AI in clinical trials is most credible where it helps clinicians spot eligible patients faster while leaving decisions to them, and the AstraZeneca and Oracle programme will be worth judging by published recruitment metrics and not by announcements. See also LCA-0061 Food Allergy Drug: Early IgE Data, Real Limits. More in our life science coverage.
What to watch next on AI in clinical trials
- A start date and design for the Abu Dhabi programme.
- Published outcome measures and first results.
- Additional health systems joining.
Frequently asked questions
How could AI help with clinical-trial recruitment?
By searching deidentified records for trial criteria and flagging likely matches to clinicians, in general terms.
Is there evidence yet?
No. The agreement was announced on 20 October 2026 and no results have been published.
Will patient data be shared with AstraZeneca?
AstraZeneca says it will not receive patient-identifiable information.
How we reported this: we relied on the companies’ releases of 20 October 2026 and public health pages. General explanations are labelled. Last updated: 20 October 2026. This article is news reporting and not medical advice.
